BAY.TI - BAYER

TLO - TLO Delayed Price. Currency in EUR
75.75
-0.37 (-0.49%)
At close: 4:46PM CEST
Stock chart is not supported by your current browser
Previous Close0.00
Open0.00
Bid0.00 x 40000
Ask0.00 x 40000
Day's Range0.00 - 0.00
52 Week Range
Volume0
Avg. VolumeN/A
Market CapN/A
BetaN/A
PE Ratio (TTM)N/A
EPS (TTM)N/A
Earnings DateN/A
Forward Dividend & YieldN/A (N/A)
Ex-Dividend DateN/A
1y Target EstN/A
  • Bayer cuts forecasts on Monsanto delay as lawsuits pile up
    Reuters Videos21 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer has cut its earnings forecast due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. Thuy Ong reports

  • Reuters5 days ago

    Bayer hemophilia treatment wins thumbs-up from EU panel

    Bayer AG's long-acting treatment for hemophilia A has won a recommendation from a European Medicines Agency (EMA) panel for the treatment of the rare genetic disorder in which blood does not clot easily. While final approvals are up to the European Commission, it generally follows recommendations from the Committee for Medicinal Products for Human Use (CHMP) and endorses them within a couple of months. The U.S. Food and Drug Administration last month approved https://in.reuters.com/article/us-bayer-fda/bayers-hemophilia-a-treatment-gets-u-s-fda-approval-idINKCN1LF17B the injection for previously treated patients and adolescents aged 12 years or older, judging it helped replace the reduced or missing protein, factor VIII, required to form blood clots.

  • The Wall Street Journal6 days ago

    [$$] Bayer Steps Up Legal Fight Over Weed Killer Blamed for Cancer

    Bayer AG is stepping up the legal defense of its flagship weedkiller, after a recent verdict in a case alleging the chemical causes cancer sent shares down sharply and raised the prospect of costly plaintiff payouts. The German company on Tuesday said it wants a California state court judge to overturn the jury’s verdict, order a new trial or reduce damages, according to a court filing. The $289 million award granted in August came in one of the first of thousands of cases filed by gardeners, farmers and others claiming Bayer’s Roundup herbicide gave them cancer.

  • Monsanto asks judge to throw out $289M award in cancer suit
    Associated Press6 days ago

    Monsanto asks judge to throw out $289M award in cancer suit

    SAN FRANCISCO (AP) — Agribusiness company Monsanto has asked a San Francisco judge to throw out a jury's $289 million award to a former school groundskeeper who said the company's Roundup weed killer left him dying of cancer.

  • Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict
    Reuters7 days ago

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate. Monsanto asked Superior Court Judge Suzanne Bolanos, who oversaw the trial, to set aside the verdict or, in the alternative, reduce the award or grant a new trial.

  • Reuters7 days ago

    Bayer's Monsanto asks U.S. court to toss $289 mln glyphosate verdict

    Bayer AG unit Monsanto on Tuesday asked a California judge to throw out a $289 million jury verdict awarded to a man who alleged the company's glyphosate-based weed-killers, including Roundup, gave him cancer. The company said in motions filed in San Francisco's Superior Court of California that the jury's decision was insufficiently supported by the evidence presented at trial by school groundskeeper Dewayne Johnson. Johnson's case, filed in 2016, was fast-tracked for trial due to the severity of his non-Hodgkin's lymphoma, a cancer of the lymph system, that he alleged was caused by years of exposure to Roundup and Ranger Pro, another Monsanto herbicide that contains glyphosate.

  • Reuters8 days ago

    Bayer says agriculture trade flows may change amid tariffs dispute

    Bayer (BAYGn.DE) said on Tuesday it would be difficult to predict 2019 earnings at its agriculture business, which now includes Monsanto, because a U.S.-Chinese trade dispute could reroute global trade flows in farming commodities. The head of Bayer's crop science division told Reuters his company could even benefit if U.S. farmers switched to grow more corn to avoid barriers to the soy trade imposed by China in response to U.S. tariffs on Chinese products. "The big unknown next year will be how U.S. farmers react to the Chinese-U.S. trade war," Liam Condon said on the sidelines of a news conference at the division's headquarters in Monheim, Germany.

  • Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern
    Zacks8 days ago

    Bayer (BAYRY) Focuses on Acquisitions, Competition a Concern

    Bayer (BAYRY) focuses on acquisitions and deals in order to boost growth as well as portfolio.

  • The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer
    Zacks8 days ago

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

    The Zacks Analyst Blog Highlights: UnitedHealth, Adobe, Amgen, UPS and Bayer

  • Bayer May Face Next Roundup Cancer Trial Sooner Than Planned
    Bloomberg12 days ago

    Bayer May Face Next Roundup Cancer Trial Sooner Than Planned

    The husband and wife in their 70s are invoking the same California law -- which gives scheduling preference to people who are terminally ill -- that allowed a school groundskeeper diagnosed with just months to live to stage the first Roundup trial this summer, resulting in a $289 million verdict. Bayer Chief Executive Officer Werner Baumann sought to assure assure investors in a Sept. 5 conference call that the merger with Monsanto will beef up the companies’ legal firepower to defeat the sprawling litigation.

  • The Wall Street Journal13 days ago

    [$$] Sanofi Poaches Bayer Manager to Lead Unit

    Sanofi hired the head of Bayer’s pharmaceuticals division to lead its Primary Care unit, one of two new divisions that the French company is creating.

  • Sanofi and Bayer Are Swapping Executives
    Bloomberg13 days ago

    Sanofi and Bayer Are Swapping Executives

    Sanofi and Bayer AG, two European drugmakers with blockbuster medicines facing headwinds, are swapping top executives. Sanofi is bringing in Bayer’s Dieter Weinand as executive vice president in charge of a new unit that combines its diabetes and cardiovascular operations with a broader group of established products, the Paris-based company said in a statement Thursday. At the same time, Stefan Oelrich, head of diabetes at Sanofi, will replace Weinand as the head of Bayer’s pharmaceuticals division in November.

  • The Wall Street Journal20 days ago

    [$$] Bayer Says More Americans Are Alleging Monsanto Weedkillers Cause Cancer

    BERLIN—Bayer AG said the number of American plaintiffs alleging its recently acquired weedkillers cause cancer has risen sharply, adding to concerns about potentially lengthy and costly litigation stemming from its acquisition of Monsanto. The German chemicals company on Wednesday also lowered its full-year earnings outlook because of delays in closing its $63 billion purchase of Monsanto, which included a portfolio of herbicides that contain glyphosate, notably flagship product Roundup. Bayer said it faced some 8,700 plaintiffs across the U.S. as of late August—mainly cancer patients who claim to have fallen ill after being exposed to the glyphosate-containing Monsanto herbicides.

  • Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout
    Zacks20 days ago

    Bayer (BAYRY) Misses on Q2 Earnings, Closes Monsanto Buyout

    Bayer (BAYRY) misses earnings estimates in the second quarter of 2018. The company completes the acquisition of Monsanto for $63 billion.

  • Reuters21 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer cut its earnings forecast on Wednesday due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. The weaker earnings forecast adds to a number of challenges facing the German drugmaker as it braces for years of legal wrangling over the alleged cancer risks of glyphosate-based weedkillers. Bayer said the number of plaintiffs seeking damages over Monsanto's Roundup and Ranger Pro herbicides had risen to 8,700 from 8,000 from last month, and said that it expected more to sue.

  • Bayer cuts forecasts on Monsanto delay as lawsuits pile up
    Reuters21 days ago

    Bayer cuts forecasts on Monsanto delay as lawsuits pile up

    Bayer cut its earnings forecast on Wednesday due to delays to its $63 billion takeover of Monsanto, and said sales of its consumer care products fell, hitting its shares, already reeling from a legal battle over the weed killer Roundup. The weaker earnings forecast adds to a number of challenges facing the German drugmaker as it braces for years of legal wrangling over the alleged cancer risks of glyphosate-based weedkillers. Bayer said the number of plaintiffs seeking damages over Monsanto's Roundup and Ranger Pro herbicides had risen to 8,700 from 8,000 from last month, and said that it expected more to sue.

  • Monsanto Still Sows the Seeds of Doubt
    Bloomberg21 days ago

    Monsanto Still Sows the Seeds of Doubt

    Investors weren’t willing to give Werner Baumann the benefit of the doubt when Bayer AG’s CEO moved to shift the drugmaker’s business to crop science by buying U.S. seeds giant Monsanto Co. Reaction to the latest unwelcome news about the deal shows the credibility deficit persists. Bayer warned on Wednesday that this year’s earnings per share would fall by a high single-digit percentage because of the timing of the Monsanto purchase. As the deal completed on June 7, a little later than hoped, the contribution to Bayer’s second-quarter numbers was small.

  • The Wall Street Journal21 days ago

    [$$] Bayer Cuts Guidance After Profit Drop

    AG (BAYN.XE) on Wednesday adjusted its 2018 guidance to reflect the acquisition of Monsanto as it reported a sharp decline in second-quarter earnings. AG (1COV.XE), which now reports as a separate company, Bayer said. The German conglomerate issued new financial guidance to reflect the Monsanto acquisition and the divestment of several businesses, including its vegetable-seeds unit.

  • Bloomberg21 days ago

    Bayer's Delays in Monsanto Purchase Hurt Earnings Forecast

    Delays to Bayer AG’s $63 billion purchase of agricultural giant Monsanto pushed the acquisition past the new unit’s busiest season, and the company said earnings for the year will be lower than forecast. Core earnings per share will probably reach about 5.70 euros to 5.90 euros, the Leverkusen, Germany-based company said Wednesday in a statement. The Monsanto acquisition, which closed in June, has made Bayer the biggest seed and agricultural chemicals maker in the world, yet it’s been overshadowed by the legal battle over the weed killer Roundup, one of Monsanto’s most important products.

  • Bayer Warns on Profit Outlook After $63 Billion Monsanto Deal
    Bloomberg21 days ago

    Bayer Warns on Profit Outlook After $63 Billion Monsanto Deal

    Bayer AG’s $63 billion Monsanto purchase has suffered regulatory delays, mounting legal claims and now will yield lower earnings for the year than earlier forecast. “The Monsanto business is very healthy,” Chief Executive Officer Werner Baumann said Wednesday in an interview with Bloomberg TV. While acquiring Monsanto made Bayer the biggest seed and agricultural-chemicals maker in the world, the purchase has been dogged by a series of challenges from regulators and legal pitfalls.

  • Bayer completes takeover of Monsanto as second-quarter profits miss estimates
    CNBC21 days ago

    Bayer completes takeover of Monsanto as second-quarter profits miss estimates

    German pharma and life sciences firm Bayer said it completed the "biggest acquisition in its history" Wednesday but delivered a series of mixed results for its second quarter.

  • Reuters22 days ago

    Factbox - Challenges facing German pharmaceutical company Bayer

    Bayer is considering job cuts and outsourcing as part of a wide-ranging review of drug research and development that will last until at least November, a person familiar with the company told Reuters. The savings that Bayer - the inventor of aspirin and maker of Yasmin birth control pills - could make as part of the overhaul would give it financial wiggle room as it competes with larger rivals to buy the right to promising treatments from biotech firms. Bayer, which is due to release second-quarter results on Wednesday, is under pressure from investors to make purchases or do licensing deals that they say are needed to ensure the long-term independence of the pharmaceutical division.

  • Bayer Aktiengesellschaft (FRA:BAYN): Is It A Smart Long Term Opportunity?
    Simply Wall St.22 days ago

    Bayer Aktiengesellschaft (FRA:BAYN): Is It A Smart Long Term Opportunity?

    In March 2018, Bayer Aktiengesellschaft (FRA:BAYN) announced its earnings update. Overall, analysts seem fairly confident, with earnings expected to grow by 32.4% in the upcoming year against the past 5-yearRead More...

  • Brazil court overturns ban on weed-killer glyphosate
    Reuters23 days ago

    Brazil court overturns ban on weed-killer glyphosate

    BRASÍLIA (Reuters) - A Brazilian court on Monday overturned an injunction banning products containing the popular weed-killer glyphosate, knocking down a previous ruling that had been set to disrupt the soy planting season set to begin this month. A Brazilian judge ruled last month to halt the registration of new glyphosate-based products in the country and to suspend existing registrations after 30 days, until health agency Anvisa issues a pending ruling on its safety. Judge Kássio Marques, of the regional federal court of the first district in Brasilia, based the ruling suspending the injunction on the government's argument that banning glyphosate and the other two agrochemicals could harm the country's economy.

  • Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A
    Zacks25 days ago

    Bayer's (BAYRY) Jivi Gets FDA Approval to Treat Hemophilia A

    Bayer's (BAYRY) Jivi gets FDA approval for the treatment of hemophilia A in previously-treated adults and adolescents aged 12 years and older.